中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

经内镜逆行胰胆管造影术后高淀粉酶血症的危险因素分析

依尔潘·艾山 高峰

引用本文:
Citation:

经内镜逆行胰胆管造影术后高淀粉酶血症的危险因素分析

DOI: 10.3969/j.issn.1001-5256.2016.01.022
详细信息
  • 中图分类号: R576

Risk factors for hyperamylasemia after endoscopic retrograde cholangiopancreatography

  • 摘要: 目的探讨经内镜逆行胰胆管造影(ERCP)术后高淀粉酶血症(PEPH)发生的危险因素。方法对2012年1月-2014年12月在新疆维吾尔自治区人民医院行治疗性ERCP并符合纳入标准的233例患者的临床资料进行回顾性分析,提取患者年龄、性别、饮酒史、单发结石、甘油三酯、民族等基本信息并详细录入ERCP术中操作、术中诊断以及并发症等情况。计数资料组间比较采用χ2检验,采用Logistic回归分析寻找PEPH发生的危险因素。结果 PEPH发生率为26.6%(62/233)。单因素分析显示女性(χ2=3.320,P=0.045)、有饮酒史(χ2=6.108,P=0.010)、胆总管狭窄(χ2=5.767,P=0.012)、单发结石(χ2=9.121,P=0.020)、十二指肠乳头憩室(χ2=28.170,P<0.001)、异常的甘油三酯(χ2=54.717,P<0.001)为PEPH发生的影响因素。多因素Logistic回归分析显示女性[比值比(OR)=1.616,P=0.025]、饮酒史(OR=2.360,P=0.010)、胆总管狭窄(OR=2.163,P=0.012)、十二指肠乳...

     

  • [1]JIA YL,JIANG H,HAN Z,et al.Clinical research on the bleeding in ERCP and EST[J].Chin J Clin Pharmacol Ther,2014,19(4):450-453.(in Chinese)贾玉良,姜华,韩真,等.ERCP与EST并发出血的相关临床研究[J].中国临床药理学与治疗学,2014,19(4):450-453.
    [2]YU L,DENG T,ZHAN YJ,et al.The clinical value of ENBD in the prevention of post-ERCP pancreatitis and hyperamylasemia in patients with common bile duct stones[J].Chin J Gastroenterol Hepatol,2012,21(4):316-318.(in Chinese)余璐,邓涛,占义军,等.ENBD预防胆总管结石ERCP术后急性胰腺炎及高淀粉酶血症的临床价值[J].胃肠病学和肝病学杂志,2012,21(4):316-318.
    [3]LI X,MENG W,ZHANG L,et al.Risk factors for postendoscopic retrograde cholangiopancreatography pancreatitis:a retrospective analysis of 7,168 cases[J].Pancreatology,2011,11(3):399-405.
    [4]TUENNEMANN J,MSSNER J,BEER S.Acute pancreatitis:guideline-based diagnosis and treatment[J].Internist(Berl),2014,55(9):1045-1056.
    [5]DING BJ,LI S,LIU C,et al.The value of preoperative MRCP on the diagnosis of CBD after cholecystectomy before operating ERCP:an analysis of 139 cases[J].Chin J Pract Intern Med,2015,35(5):449-450.(in Chinese)丁百静,李生,刘充,等.ERCP术前经磁共振胰胆管造影对胆囊切除术后胆总管结石139例诊断价值探讨[J].中国实用内科杂志,2015,35(5):449-450.
    [6]SHAH TU,LIDDLE R,BRANCH MS,et al.Pilot study of aprepitant for pr evention of post-ERCP pancreatitis in high risk patients:a phaseⅡrandomized,double-blind placebo controlled trial[J].JOP,2012,13(2):514-518.
    [7]WANG P,LI ZS,LIU F,et al.Risk factors for ERCP-related complications:a prospective multicenter study[J].Am J Gastroenterol,2009,104(7):31-40.
    [8]TSUJINO T,KOMATSU Y,ISAYAMA H,et al.Ulinastatin for pancreatitis after endoscopic retrograde cholangiopancreatography:a randomized,controlled trial[J].Clin Gastroenterol Hepatol,2005,3(1):376-383.
    [9]ELMUNZER BJ,SCHEIMAN JM,LEHMAN GA,et al.A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis[J].N Engl J Med,2012,366(11):1414-1422.
    [10]KOBAYASHI Y,KANEMITU T,KAMOTO A,et al.Painless acute pancreatitis associated with sorafenib treatment:a case report[J].Med Oncol,2011,28(3):463-465.
    [11]FREEMAN LD,KRIO JA,NDSON VB,et al.Risk factors of post-ERCP pancreatitis:a pmspective,muhicenteraudypl[J].Gastrintesf Eudose,2001,54(4):425-434.
    [12]WANG P,LI ZS,LIU F,et al.Risk factors for ERCP-related complications:a prospective multicenter study[J].Am J Gastroentero,2009,104(1):31-40.
    [13]CHOUDHARY A,BECHTOLD ML,ARIF M,et al.Pancreatic stents for prophylaxis against post-ERCP pancreatitis:a meta-analysis and systematic review[J].Gastrointest Endosc,2011,73(4):275-282.
    [14]LEGHARI A,GHAZANFAR S,QURESHI S,et al.Frequency and risk factors in the post-ERCP pancreatitis in a tertiary care centr[J].J Coll Physicians Surg Pak,2013,23(9):620-624.
    [15]CHEN JJ,WANG XM,LIU XQ,et al.Risk factors for post-ERCP pancreatitis:a systematic review of clinical trials with a large sample size in the past 10 years[J].Eur J Med Res,2014,19(26):1-7.
  • 加载中
计量
  • 文章访问数:  1736
  • HTML全文浏览量:  16
  • PDF下载量:  431
  • 被引次数: 0
出版历程
  • 收稿日期:  2015-05-11
  • 出版日期:  2016-01-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回